| Name | Title | Contact Details |
|---|---|---|
Jing Zhang |
WW VP, Regulatory | Profile |
Access Genetics LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
Sage Rutty & Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
ATCC, the premier global biological materials resource and standards organization serves and supports the scientific community with industry-standard products and innovative solutions. With the world’s largest and most diverse collection of human and animal cell lines, microorganisms, nucleic acids, molecular genomic tools, and biological products, ATCC is a trusted resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge.